Abstract It was shown that osteopontin (OPN), a glycophosphoprotein, plays divergent roles in cancer progression. In addition to multiple intra-and extracellular functions, it facilitates migration of tumour cells, has crucial role in cell adhesion and is associated with increased metastasis formation. In previous studies, we performed global gene expression profiling on a series of primary melanoma samples and found that OPN was significantly overexpressed in ulcerated melanomas. The major purpose of this study was to define OPN expression in primary melanomas with differing biological behaviours. OPN mRNA expression was analysed by quantitative reverse transcription polymerase chain reaction (qRT-PCR) in primary melanoma tissues. Immunohistochemistry was performed using a tissue microarray. Cox regression tests were used for survival analysis. Greater than 50 % of the tissues exhibited high protein expression that was significantly associated with tumour thickness and metastasis. OPN mRNA expression was significantly increased in thicker melanomas and lesions with an ulcerated surface. Increased expression was primarily detected in advanced-stage tumours. A multivariate Cox regression analysis revealed that high OPN expression, tumour thickness and metastasis were significantly associated with reduced relapse-free survival. In summary, high OPN mRNA and protein expression were associated with a less favourable clinical outcome of primary melanoma patients. We determined that OPN is a significant predictive factor for the survival of primary melanoma patients. Based on our and others data, the high expression of OPN may have a crucial stimulatory role in tumour progression and metastasis formation, which, thus, have been proposed as potential targets for cancer diagnosis and therapy.
Introduction
Malignant melanoma is the most aggressive type of skin cancer, with rapidly increasing incidence worldwide [1] [2] [3] . Despite previous intensive research to advance our understanding of melanoma progression, therapeutic options remain limited, and melanoma is mainly cured surgically [4, 5] . New therapeutic targets and diagnostic tools are especially warranted.
Osteopontin (OPN) is a multifunctional extracellular matrix protein that is produced by numerous cell types [6] [7] [8] [9] [10] [11] . OPN plays important roles in cancer cell adhesion, cell motility and survival [12] [13] [14] [15] [16] . Previous reports indicated that the OPN is a crucial participant in the regulation of cancer cell signalling, ultimately leading to tumour progression [17] [18] [19] [20] [21] [22] .
Several studies indicate that OPN protein is overexpressed in the majority of human cancers, including malignant melanoma, and is associated with tumour progression [14, [23] [24] [25] [26] [27] [28] [29] [30] .
Extensive microarray analyses of melanomas demonstrated that OPN also plays a role in melanoma progression [14, 28, 31, 32] .
Several research groups have studied OPN expression at both the protein and mRNA levels in primary and metastatic melanomas and demonstrated that OPN expression is significantly increased in melanoma samples compared with naevi [14, 28, 31] . One of these studies did not identify an association between protein expression level and the clinicopathological parameters of primary melanoma tumours [14] . Other studies have reported that OPN was significantly overexpressed in primary and metastatic melanomas, but none of these studies reported an unequivocal correlation among OPN expression levels and the primary melanoma thickness, stage and relapse-free survival [24] . According to the majority of the studies, OPN is a specific tumour marker candidate; therefore, OPN might serve as a potential target for therapeutic intervention to control melanoma progression [24, 33, 34] . However, the prognostic relevance of OPN in melanoma has not been fully elucidated.
In previous studies, we performed global gene expression profiling on a series of primary melanoma samples and report that OPN was significantly associated with poor clinical outcome [35] . In this study, our aim was to confirm our previous microarray data; furthermore, we sought to elucidate OPN expression at both the mRNA and protein levels in primary melanoma samples using quantitative polymerase chain reaction (PCR), tissue microarray and immunohistochemistry. To characterise the clinical parameters that might impact molecular alterations, we also aimed to define the association between OPN expression and the clinicopathological parameters of melanoma patients. Furthermore, we analysed the relationship between OPN expression and melanoma patient survival.
Material and methods

Melanoma tissue samples
Melanoma tissues were obtained from the Department of Dermatology, University of Debrecen, Hungary. This study was approved by the Regional and Institutional Ethics Committee of the University of Debrecen Clinical Center and performed according to the relevant regulations. Written informed consent was obtained from the patients. Lesions were diagnosed based on formalin-fixed paraffin-embedded (FFPE) tissue sections that were stained with haematoxylineosin (H&E). A total of 93 tumours were examined using immunohistochemistry, 28 tumours were analysed by realtime quantitative reverse transcription polymerase chain reaction (qRT-PCR) and 14 tumours were analysed using both methods. The clinicopathological data of the primary melanomas are summarised in Table 1 .
RNA extraction and qRT-PCR
The RNeasy Mini Kit (QIAGEN GmbH, Hilden, Germany) was used to isolate the total RNA from 28 fresh melanoma tissues according to manufacturer's protocol. The quantities of the RNA samples were determined using a NanoDrop ND-1000 UV-Vis Spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). Reverse transcription (RT) was performed on total RNA (600 ng) using the High-Capacity cDNA Reverse Transcription Kit according to manufacturer's protocol (Life Technologies Corporation, Carlsbad, CA, USA). TaqMan one-step RT-PCR was used to determine the mRNA level of the OPN gene. Each reaction contained 150 ng of total sample RNA, and the reactions were run in triplicate on an ABI-PRISM 7000 instrument (Applied Biosystems, Carlsbad, CA, USA). PCR Master Mix and assays (Hs00167093_m1 OPN targeting the exon 3-4 boundary) were obtained from Life Technologies. PCR data were analysed using the Livak method (2 − Δ Δ C t ) using glyceraldehyde-3-phosphate dehydrogenase (GAPDH; Hs99999905_m1) and beta-actin (ACTB; Hs99999903_m1) as the reference (endogenous controls) genes and naevi as the calibrator sample [36] .
Tissue microarrays and immunohistochemistry
A total of 93 FFPE melanomas were included in the tissue microarray analysis (TMA) [37] . The clinicopathological data of the primary melanomas are summarised in Table 1 . Tissue sections (4 μm) of the original blocks were first stained with H&E and then reviewed by pathologists to select the area to be punched automatically using the TMA Master (Carl Zeiss, Jena, Germany). We used triplicate 1-mm tumour cores from each donor block. Serial sections of 4 μm were excised from the TMA blocks and used for immunohistochemical investigations following H&E validation of the sample spots. After deparaffinisation and blocking the endogenous peroxidases (1 % H 2 O 2 for 10 min at RT) and non-specific binding sites, we retrieved antigens in 1 mM boiling citrate buffer (pH 6, 3 min). Then, the primary antibody, rabbit polyclonal antiosteopontin IgG (Thermo Scientific, USA), was added at a 1:20 dilution and incubated for 1 h at room temperature (RT). After incubation with the primary antibody, the samples were stained using the EnVision detection system (DAKO Inc., Carpinteria, CA, USA) and the VIP Peroxidase Substrate Kit (Vector Laboratories LTD, Peterborough, UK). The nuclei were counterstained with methyl green (Vector Laboratories LTD, Peterborough, UK). The primary antibody was omitted in negative controls. The HeLa cervical cancer cell line was used as a positive control. The slides were digitised using the Mirax Scan slide scanning device (Carl Zeiss, Jena, Germany) as previously described [38] . Digital images were displayed using Mirax Viewer software (Carl Zeiss, Jena, Germany) and evaluated by two dermatopathologists who were blind with respect to the sample data. We determined the tumour cell proportion score and intensity score. The proportion score included the fraction of positively stained tumour cells as follows: 0=none, 1+=<5 %, 2+=5-50 % and 3+=>50 %. The estimated average staining intensity of the positive tumour cells was expressed as follows: 0=none, 1+=weak, 2+=moderate and 3+=strong ( Fig. 1 ).
Statistical analysis
Statistical Package for the Social Sciences (SPSS) 22.0 software (SPSS Inc., Chicago, IL, USA) was used for statistical 
Results
OPN mRNA expression in primary melanomas
OPN gene expression analysis was performed in 28 primary melanomas. A greater than twofold increase in the OPN mRNA level was found in 93 % (26/28) of these melanomas. We determined the relationship between gene expression levels and clinicopathological parameters. OPN mRNA expression was significantly increased in thicker melanomas (greater than 4.00 mm) and ulcerated lesions; furthermore, OPN was present mainly in late-stage tumours (Clark levels IV and V) (Fig. 2) . Fourteen overlapping samples were used to compare the gene and protein expression levels in the same tumour samples (Table 2) . Increased OPN mRNA expression levels were detected in the majority of primary melanoma samples and were associated with different degrees of protein expression. A few contradictions may result from the fact that the samples used for the qRT-PCR and immunohistochemical study were derived from a part of the tumour that exhibits significant normal cell contamination. We did not observe any correlation between OPN protein levels and mRNA expression.
Association between OPN protein expression and clinicopathological characteristics in primary melanomas
We examined OPN protein expression levels in 93 primary melanomas. In total, 87 % (81/93) of the melanoma samples were positive for OPN. The remaining 12 samples showed no OPN positivity. Greater than 50 % of primary melanomas with poor clinical outcome exhibited increased OPN protein 
Discussion
In the last decade, several studies have defined the important role of OPN in tumourigenesis and metastasis. In human malignant melanoma, OPN expression is significantly associated with reduced relapse-free survival and additional histological parameters that are associated with poor clinical outcome [7, 24, 29, 33] . OPN is a prognostic marker in a variety of cancers [30, [39] [40] [41] . In metastatic and primary melanomas, OPN has also been suggested to be a novel promising biomarker for the detection of metastases in patients with primary melanomas [24, [42] [43] [44] [45] . Atai et al. performed a meta-analysis across several distinct cancer microarray data sets and found increased OPN gene expression in at least 90 % of melanoma patients [46] . Our group recently published a comprehensive microarray analysis in primary melanomas and reported that increased OPN mRNA expression in melanomas is characteristic of less favourable clinical outcomes [35] . Our present study successfully validated the aforementioned microarray results by qRT-PCR, revealing that increased OPN mRNA expression is significantly associated with later-stage melanomas (Clark levels IV-V) with an ulcerated surface and higher thickness (greater than 4.00 mm). Previous studies have reported that increased OPN mRNA expression is associated with unfavourable patient prognosis in human cancers, including melanoma [9, 29] . In addition, we extended our studies to OPN protein levels and therefore fabricated tissue microarray platforms for 93 primary melanomas. By performing immunohistochemistry on the primary melanoma specimens, we observed increased OPN protein levels in samples with poor prognosis. Notably, increasing immunostaining was significantly associated with Breslow tumour thickness and metastatic capacity, indicating a role for OPN in melanoma progression [7, 24] . However, our protein and gene expression results did not reveal clear relationships in all samples, and on average, we observed that increased OPN mRNA levels were associated with strong antigen positivity. The main reason for this phenomenon might be due to the relatively limited number of melanoma specimens. Several previous studies have simultaneously investigated OPN mRNA and protein expression in various cancers, including melanoma, and found that OPN was overexpressed in tumours that were associated with less favourable prognosis [9, 28, 31, 32] In a multivariate Cox regression analysis, increased OPN expression emerged as a predictor of survival after thickness and metastasis. Patients with increased OPN expression (a score of 2 or 3) exhibited a 2.02-fold increased risk of death from disease (p=0.050), which is consistent with that described in the literature [15, 24] . Elevated OPN expression is associated with advanced stage, tumour invasion and metastasis in multiple cancers. The function of OPN is versatile and involves the induction of multiple signalling pathways (PI 3′-kinase/ Akt, NF-kB) by integrin and CD44 receptors that mediate metastatic processes [8, 18, 19] .
In summary, we demonstrate that tumour OPN expression is a strong predictor of poor prognosis. A multivariate analysis confirmed that OPN is a significant predictive factor for primary melanoma patient survival. This study provides further evidence regarding the importance of OPN in the biology of melanoma. Our findings are consistent with those of previous studies and support the hypothesis that OPN expression is a potential biomarker of melanoma progression [29, 33] . 
